CN100584950C - 嵌合多肽及其用途 - Google Patents

嵌合多肽及其用途 Download PDF

Info

Publication number
CN100584950C
CN100584950C CN200480009095A CN200480009095A CN100584950C CN 100584950 C CN100584950 C CN 100584950C CN 200480009095 A CN200480009095 A CN 200480009095A CN 200480009095 A CN200480009095 A CN 200480009095A CN 100584950 C CN100584950 C CN 100584950C
Authority
CN
China
Prior art keywords
polypeptide
cells
dna
activity
chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200480009095A
Other languages
English (en)
Chinese (zh)
Other versions
CN1768142A (zh
Inventor
克里斯蒂娜·库恩
安德拉斯·西蒙克西特斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adria Sell Co
Original Assignee
INTERNAT CT FOR GENETIC ENGINE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INTERNAT CT FOR GENETIC ENGINE filed Critical INTERNAT CT FOR GENETIC ENGINE
Publication of CN1768142A publication Critical patent/CN1768142A/zh
Application granted granted Critical
Publication of CN100584950C publication Critical patent/CN100584950C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21004—Type II site-specific deoxyribonuclease (3.1.21.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
CN200480009095A 2003-04-18 2004-04-16 嵌合多肽及其用途 Expired - Fee Related CN100584950C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000821A ITMI20030821A1 (it) 2003-04-18 2003-04-18 Polipeptidi chimerici e loro uso.
ITMI2003A000821 2003-04-18

Publications (2)

Publication Number Publication Date
CN1768142A CN1768142A (zh) 2006-05-03
CN100584950C true CN100584950C (zh) 2010-01-27

Family

ID=33187374

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200480009095A Expired - Fee Related CN100584950C (zh) 2003-04-18 2004-04-16 嵌合多肽及其用途

Country Status (16)

Country Link
US (3) US20060292629A1 (enExample)
EP (1) EP1616011B1 (enExample)
JP (2) JP4794432B2 (enExample)
KR (2) KR101360781B1 (enExample)
CN (1) CN100584950C (enExample)
AT (1) ATE374826T1 (enExample)
AU (1) AU2004230254B2 (enExample)
CA (1) CA2522525A1 (enExample)
CY (1) CY1107115T1 (enExample)
DE (1) DE602004009301T2 (enExample)
DK (1) DK1616011T3 (enExample)
ES (1) ES2293247T3 (enExample)
IT (1) ITMI20030821A1 (enExample)
PL (1) PL1616011T3 (enExample)
PT (1) PT1616011E (enExample)
WO (1) WO2004092194A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104193826A (zh) * 2014-09-17 2014-12-10 山东大学齐鲁医院 一种融合多肽及其在制备抗肿瘤药物中的应用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20030821A1 (it) * 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.
NL1027479C2 (nl) * 2004-10-21 2006-05-01 Synvolux Ip B V Bescherming van biologisch actieve moleculen met behulp van amphifielen.
ES2341796T3 (es) * 2005-02-18 2010-06-28 Astrazeneca Ab Metodo para determinar la capacidad de respuesta a los inhibidores de chk1.
GB0609119D0 (en) * 2006-05-09 2006-06-21 Univ Birmingham Histones
US8552168B2 (en) * 2007-05-11 2013-10-08 The Regents Of The University Of California Nucleic acids for inducing expression of transcripts and proteins and methods for making and using them
AU2015216822A1 (en) 2014-02-17 2016-09-01 Centre Leon Berard Predictive method of characterizing the radiosensitivity and tissular reaction of a patient to therapeutic ionizing radiation
CA3019629A1 (en) * 2016-04-12 2017-10-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methylmalonyl coenzyme a mutase (mcm) fusion constructs for the treatment of disorders associated with mcm deficiency
JP6925003B2 (ja) * 2016-05-10 2021-08-25 公立大学法人横浜市立大学 非相同末端連結欠損細胞及びその利用
MX2018014366A (es) * 2016-05-27 2019-04-11 Synthex Inc Interfaces de proteina.
KR20190020727A (ko) * 2016-06-09 2019-03-04 알마마 테르 스투디오룸 유니베르시타‘ 디 볼로냐 변형된 당단백질 b를 갖는 헤르페스 바이러스
EP3638317A4 (en) 2017-06-15 2021-03-17 The Regents of The University of California TARGETED NONVIRAL DNA INSERTIONS
KR102770787B1 (ko) 2017-10-27 2025-02-19 더 리전트 오브 더 유니버시티 오브 캘리포니아 내인성 t 세포 수용체의 표적화된 대체
WO2019104244A1 (en) 2017-11-22 2019-05-31 Synthex, Inc. Peptides for inhibiting rad51
PE20241173A1 (es) 2021-10-14 2024-05-28 Arsenal Biosciences Inc Celulas inmunitarias que tienen arnhc coexpresados y sistemas de compuerta logica
CA3238209A1 (en) 2021-12-16 2023-06-22 Christian Kuhne Cell penetrating polypeptides (cpps) and their use in human therapy
CN116023512A (zh) * 2023-02-16 2023-04-28 浙江大学 一条靶向dna损伤修复蛋白的多肽及其用途
EP4480497A1 (en) 2023-06-21 2024-12-25 RDP Pharma AG Bio-conjugates for oncology

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046386A2 (en) * 1999-02-03 2000-08-10 The Children's Medical Center Corporation Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
WO2000058488A2 (en) * 1999-03-31 2000-10-05 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
WO2002096952A2 (en) * 2001-05-25 2002-12-05 Lorantis Limited Conjugate of a transport protein and a protein for modulation of notch signalling

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747641A (en) * 1989-12-21 1998-05-05 Biogen Inc Tat-derived transport polypeptide conjugates
WO2001074905A1 (en) * 2000-04-03 2001-10-11 Antisoma Research Limited Compounds for targeting
EP1342781A1 (en) * 2002-03-09 2003-09-10 ARTEMIS Pharmaceuticals GmbH Recombinase fusion protein with enhanced cellular uptake
US9447434B2 (en) * 2002-09-05 2016-09-20 California Institute Of Technology Use of chimeric nucleases to stimulate gene targeting
ITMI20030821A1 (it) * 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046386A2 (en) * 1999-02-03 2000-08-10 The Children's Medical Center Corporation Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
WO2000058488A2 (en) * 1999-03-31 2000-10-05 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
WO2002096952A2 (en) * 2001-05-25 2002-12-05 Lorantis Limited Conjugate of a transport protein and a protein for modulation of notch signalling

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Fusio with an RNA binding domain to confer target RNAspecificity to an RNase:design and engineering ofTat-RNase H that specifically recognizes and cleaves HIV-1RNA in vitro.Yuri F. Melekhovets,Sadhna Joshi.NUCLEIC ACIDS RESEARCH,Vol.24 No.10. 1996 *
Intercellular delivery of functional p53 by the herpesvirusprotein VP22. Anne Phelan,Gill Elliott,Peter O'Hare.NATURE BIOTECHNOLOGY,Vol.16 No.5. 1998 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104193826A (zh) * 2014-09-17 2014-12-10 山东大学齐鲁医院 一种融合多肽及其在制备抗肿瘤药物中的应用
CN104193826B (zh) * 2014-09-17 2018-02-23 山东大学齐鲁医院 一种融合多肽及其在制备抗肿瘤药物中的应用

Also Published As

Publication number Publication date
KR20110074948A (ko) 2011-07-04
KR101247704B1 (ko) 2013-03-26
WO2004092194A3 (en) 2005-03-17
KR20060003029A (ko) 2006-01-09
CN1768142A (zh) 2006-05-03
US20110033384A1 (en) 2011-02-10
CY1107115T1 (el) 2012-01-25
JP4794432B2 (ja) 2011-10-19
JP2006523448A (ja) 2006-10-19
CA2522525A1 (en) 2004-10-28
EP1616011B1 (en) 2007-10-03
DE602004009301T2 (de) 2008-07-17
WO2004092194A2 (en) 2004-10-28
AU2004230254B2 (en) 2008-10-02
JP2011182792A (ja) 2011-09-22
PL1616011T3 (pl) 2008-05-30
PT1616011E (pt) 2008-01-07
US20060292629A1 (en) 2006-12-28
ES2293247T3 (es) 2008-03-16
ITMI20030821A1 (it) 2004-10-19
DK1616011T3 (da) 2008-02-04
DE602004009301D1 (de) 2007-11-15
US20150018409A1 (en) 2015-01-15
KR101360781B1 (ko) 2014-04-24
AU2004230254A1 (en) 2004-10-28
ATE374826T1 (de) 2007-10-15
EP1616011A2 (en) 2006-01-18

Similar Documents

Publication Publication Date Title
CN100584950C (zh) 嵌合多肽及其用途
Stracker et al. The Mre11 complex and the metabolism of chromosome breaks: the importance of communicating and holding things together
Bouquet et al. The loss of γH2AX signal is a marker of DNA double strand breaks repair only at low levels of DNA damage
EP0781331B1 (en) Improvements in or relating to binding proteins for recognition of dna
Bharti et al. Molecular functions and cellular roles of the ChlR1 (DDX11) helicase defective in the rare cohesinopathy Warsaw breakage syndrome
Siaud et al. Plasticity of BRCA2 function in homologous recombination: genetic interactions of the PALB2 and DNA binding domains
Hegde et al. Enhancement of NEIL1 protein-initiated oxidized DNA base excision repair by heterogeneous nuclear ribonucleoprotein U (hnRNP-U) via direct interaction
Sánchez et al. Monitoring histone methylation (H3K9me3) changes in live cells
Choi et al. Meiosis-specific cohesin complexes display essential and distinct roles in mitotic embryonic stem cell chromosomes
Fernández et al. Global chromatin mobility induced by a DSB is dictated by chromosomal conformation and defines the HR outcome
US20060141529A1 (en) Compositions, kits and assays containing reagents directed to cortactin and an ARG/ABL protein kinase
JP2001508868A (ja) 細胞ｄｎａ 修復活性の調節に関するアッセイ、剤、治療及び診断
US20240043480A1 (en) Activating mitotic checkpoint control mechanisms
Rieu et al. The F-box cofactor UFO redirects the LEAFY floral regulator to novel cis-elements
Jaff Identification of Regions Required for CDCA7 Interaction with DNA Damage Repair Machinery
Susvirkar Biochemical characterization of human Shieldin complex
Islam Development of Systems for Expression, Purification, and CK2-Mediated Phosphorylation of the Histone Oligomers
Lomvardas et al. DNA sequence-induced solid phase transitions as a solution to the genome folding paradox
Brozkova The role of the human SMC5/6 complex in genome stability
Wu Roles of NBS1 and BRCA2 cancer susceptibility genes in the maintenance of genome stability
Espinoza-Corona et al. Ubiquitylation and SUMOylation: An Orchestrated Regulation During DNA Damage Repair
Pratt Interaction properties of hnRNP-U family proteins AND SIM: SUMO interaction of the deSUMOylation enzyme SENP7 and the SIMs role in protein functionality
Erdemir Identification of the Role of the Nuclear Matrix Protein CID in DNA Repair and Recombination
Miller Characterization of the ubiquitin-interacting motif: Ability to bind ubiquitin, promote ubiquitylation and potential role in Huntington's disease, a neurodegenerative disorder
Silver The Identification of Novel Ligands for Cell Surface Receptors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: ADRIACIER CO.,LTD.

Free format text: FORMER OWNER: INTERNATIONAL INHERITANCE ENGINEERING AND BIOTECHNOLOGY CENTER

Effective date: 20100115

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20100115

Address after: Trieste city of Italy

Patentee after: Adria Sell Co.

Address before: Trieste city of Italy

Patentee before: Internat Ct For Genetic Engine

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100127

Termination date: 20180416

CF01 Termination of patent right due to non-payment of annual fee